AstraZeneca will establish a new global headquarters and research center at the Cambridge Biomedical Campus in England. The move is in line with the drugmaker's plan to build strategic global R&D centers in the U.S., U.K. and Sweden to boost pipeline productivity and establish the firm as an innovation leader. AstraZeneca will invest about $500 million in the site, which will employ roughly 2,000 highly skilled workers by 2016.

Related Summaries